Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cordis/Volcano

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Cordis will promote Volcano's intravascular ultrasound technology alongside its Cypher drug-eluting stents in Europe under a non-exclusive collaboration announced Nov. 8. Currently, only 3.5% of percutaneous coronary interventions performed in Europe use IVUS imaging technology to guide stent placement. Volcano and Johnson & Johnson are also both cosponsors of the ADAPT-DES study, which will enroll from 11,000 to 15,000 patients, including 3,000 patients who will be imaged with Volcano's Eagle Eye Gold IVUS catheter during initial drug-eluting stent placement and in follow-up assessments of dual antiplatelet therapy (1"The Gray Sheet" Oct. 29, 2007, p. 8)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT025463

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel